Study to investigate the Potential Effect of Benralizumab on the antibody response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients with Severe Asthma (ALIZE) - Trial 2016-001717-24

Name: Clinical Trial 2016-001717-24
Creator: AstraZeneca AB
Keywords: Asthma, clinical trial

Access comprehensive clinical trial information for 2016-001717-24 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca AB and is currently status unknown. The study focuses on Asthma.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2016-001717-24

Trial Details

EU Clinical Trials Register • 2016-001717-24

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Study to investigate the Potential Effect of Benralizumab on the antibody response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients with Severe Asthma (ALIZE)

Study Focus

Disease/Condition

Asthma

Sponsor & Location

Primary Sponsor

AstraZeneca AB

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

1. Clinically important pulmonary disease other than asthma (eg, active lung infection,

ICD-10 Classifications

Asthma

Asthma, unspecified

Nonallergic asthma

Mixed asthma

Predominantly allergic asthma

Data Source

Registry

EU Clinical Trials Register

Trial ID

2016-001717-24

Type

Non-Device Trial